Tiziana Life Sciences plc

PDMR Dealing

New York/London, 14 January 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that on the 13 January 2020 it was informed that on that date, Panetta Partners Limited, an entity closely associated with Gabriele Cerrone, Executive Chairman, bought 28,500 Ordinary Shares at a price of 43 pence per Ordinary Share, as set out below.

The information set out below is provided in accordance with the requirements of Regulation 19(3) of the EU Market Abuse Regulation No 596/2014:

As a result of this transaction Mr Cerrone's interests in the underlying ordinary shares of the Company increases from 64,318,425 (47.066%) to 64,346,925 (47.087%). Mr Cerrone's interests in the ordinary shares of the Company are based on a holding of 63,680,404 ordinary shares held by Planwise Limited and voting rights in respect of 666,521 ordinary shares held by Panetta Partners Limited (as shares and via ADSs). Mr Cerrone is considered beneficially interested in the holdings of Panetta Partners Limited and Planwise Limited.

For more information go to http://www.tizianalifesciences.com

Contacts: